Nuveen’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-106,864
| Closed | -$2.15M | – | 3800 |
|
|
2026
Q1 | $2.15M | Sell |
106,864
-265
| -0.2% | -$4.27K | ﹤0.01% | 2250 |
|
|
2025
Q4 | $1.73M | Buy |
107,129
+27,371
| +34% | +$362K | ﹤0.01% | 2349 |
|
|
2025
Q3 | $971K | Buy |
79,758
+11,219
| +16% | +$155K | ﹤0.01% | 2638 |
|
|
2025
Q2 | $775K | Buy |
68,539
+31,218
| +84% | +$382K | ﹤0.01% | 2711 |
|
|
2025
Q1 | $4.93M | Sell |
37,321
-43,122
| -54% | -$440K | ﹤0.01% | 1935 |
|
|
2024
Q4 | $681K | Hold |
80,443
| – | – | ﹤0.01% | 2875 |
|
|
2024
Q3 | $932K | Hold |
80,443
| – | – | ﹤0.01% | 2795 |
|
|
2024
Q2 | $948K | Buy |
80,443
+9,376
| +13% | +$109K | ﹤0.01% | 2750 |
|
|
2024
Q1 | $843K | Hold |
71,067
| – | – | ﹤0.01% | 2767 |
|
|
2023
Q4 | $871K | Buy |
71,067
+10,115
| +17% | +$92K | ﹤0.01% | 2798 |
|
|
2023
Q3 | $587K | Sell |
60,952
-831
| -1% | -$8.49K | ﹤0.01% | 2788 |
|
|
2023
Q2 | $556K | Hold |
61,783
| – | – | ﹤0.01% | 2890 |
|
|
2023
Q1 | $485K | Sell |
61,783
-7,163
| -10% | -$53.4K | ﹤0.01% | 2813 |
|
|
2022
Q4 | $982K | Sell |
68,946
-10,832
| -14% | -$58K | ﹤0.01% | 2683 |
|
|
2022
Q3 | $1.16M | Buy |
79,778
+535
| +0.7% | +$7.48K | ﹤0.01% | 2679 |
|
|
2022
Q2 | $779K | Buy |
79,243
+15,338
| +24% | +$169K | ﹤0.01% | 2895 |
|
|
2022
Q1 | $962K | Buy |
63,905
+805
| +1% | +$11.6K | ﹤0.01% | 2828 |
|
|
2021
Q4 | $796K | Sell |
63,100
-59,022
| -48% | -$940K | ﹤0.01% | 2929 |
|
|
2021
Q3 | $2.35M | Sell |
122,122
-237
| -0.2% | -$4.8K | ﹤0.01% | 2597 |
|
|
2021
Q2 | $2.93M | Buy |
122,359
+39,269
| +47% | +$1.03M | ﹤0.01% | 2530 |
|
|
2021
Q1 | $1.3M | Sell |
83,090
-748
| -0.9% | -$19.7K | ﹤0.01% | 2802 |
|
|
2020
Q4 | $1.59M | Sell |
83,838
-26,953
| -24% | -$462K | ﹤0.01% | 2620 |
|
|
2020
Q3 | $1.4M | Buy |
110,791
+256
| +0.2% | +$3.2K | ﹤0.01% | 2535 |
|
|
2020
Q2 | $1.34M | Buy |
110,535
+53,863
| +95% | +$573K | ﹤0.01% | 2496 |
|
|
2020
Q1 | $433K | Buy |
56,672
+17,193
| +44% | +$232K | ﹤0.01% | 2818 |
|
|
2019
Q4 | $703K | Buy |
39,479
+7,279
| +23% | +$95K | ﹤0.01% | 2812 |
|
|
2019
Q3 | $374K | Sell |
32,200
-29,706
| -48% | -$480K | ﹤0.01% | 3019 |
|
|
2019
Q2 | $1.37M | Buy |
+61,906
| New | +$1.45M | ﹤0.01% | 2610 |
|
Other funds holding KALV
Nuveen's KALV Position: Q2 2026 in Review
Nuveen sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 106,864 shares — an estimated $2.15M sold.
Nuveen first reported a position in KALV in Q2 2019 and held it in 28 quarters. The position peaked at $4.93M in Q1 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Nuveen reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Nuveen sold 106,864 KalVista Pharmaceuticals shares in Q2 2026, an estimated $2.15M.
- Nuveen first reported a position in KalVista Pharmaceuticals in Q2 2019 and held it in 28 quarters.
- Nuveen's KalVista Pharmaceuticals position peaked at $4.93M in Q1 2025.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.